Skyrizi now PBS listed

For Community

For Fellows and Trainees

For Health Professionals

Posted 10 months ago

Skyrizi  (risankizumab) is now Pharmaceutical Benefits Scheme listed for the treatment of severe chronic plaque psoriasis.

The drug is an interleukin 23 (IL-23) inhibitor and is indicated for treatment  in adults who are candidates for phototherapy or systemic therapy.

Please review the Consumer Medicines Information here for further safety information.